- Home
- CALC vs RADX Comparison
CALC vs RADX Comparison
Compare CALC & RADX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CALC
- RADX
- Stock Information
- Founded
- CALC 2011
- RADX 2021
- Country
- CALC United States
- RADX Australia
- Employees
- CALC N/A
- RADX N/A
- Industry
- CALC Biotechnology: Pharmaceutical Preparations
- RADX
- Sector
- CALC Health Care
- RADX
- Exchange
- CALC Nasdaq
- RADX NYSE
- Market Cap
- CALC 20.9M
- RADX 31.8M
- IPO Year
- CALC N/A
- RADX N/A
- Fundamental
- Price
- CALC $1.50
- RADX $4.07
- Analyst Decision
- CALC Strong Buy
- RADX Strong Buy
- Analyst Count
- CALC 3
- RADX 1
- Target Price
- CALC $16.33
- RADX $15.00
- AVG Volume (30 Days)
- CALC 22.8K
- RADX 32.5K
- Earning Date
- CALC 05-12-2025
- RADX 02-26-2025
- Dividend Yield
- CALC N/A
- RADX N/A
- EPS Growth
- CALC N/A
- RADX N/A
- EPS
- CALC N/A
- RADX N/A
- Revenue
- CALC N/A
- RADX $204,609.00
- Revenue This Year
- CALC N/A
- RADX N/A
- Revenue Next Year
- CALC N/A
- RADX N/A
- P/E Ratio
- CALC N/A
- RADX N/A
- Revenue Growth
- CALC N/A
- RADX N/A
- 52 Week Low
- CALC $1.43
- RADX $3.50
- 52 Week High
- CALC $6.27
- RADX $50.82
- Technical
- Relative Strength Index (RSI)
- CALC 30.83
- RADX N/A
- Support Level
- CALC $1.43
- RADX N/A
- Resistance Level
- CALC $1.67
- RADX N/A
- Average True Range (ATR)
- CALC 0.12
- RADX 0.00
- MACD
- CALC 0.01
- RADX 0.00
- Stochastic Oscillator
- CALC 15.56
- RADX 0.00
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
About RADX RADIOPHARM THERANOSTICS LIMITED SPON ADS EACH REP 300 ORD
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.